Ken Griffin In Med Pharmaceuticals Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in In Med Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 56,666 shares of INM stock, worth $252,730. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,666
Previous 12,097
368.43%
Holding current value
$252,730
Previous $3,000
333.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding INM
# of Institutions
16Shares Held
1.14MCall Options Held
0Put Options Held
0-
Advisor Shares Investments LLC Bethesda, MD733KShares$3.27 Million0.03% of portfolio
-
Ubs Group Ag212KShares$945,6930.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny50.3KShares$224,3200.0% of portfolio
-
Hrt Financial LP New York, NY38.4KShares$171,1250.0% of portfolio
-
Virtu Financial LLC New York, NY28.4KShares$126,7300.0% of portfolio
About InMed Pharmaceuticals Inc.
- Ticker INM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 908,761
- Market Cap $4.05M
- Description
- InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in precl...